Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

Publication date: Oct 04, 2019

This is a multi-center, randomized, parallel arm, double-blind study with a total duration of subjects’ participation of 48 weeks. Approximately 260 participants with relapsing-remitting multiple sclerosis will be randomized to receive 12 doses of either PB006 or EU-licensed Natalizumab.

Concepts Keywords
Alemtuzumab Alemtuzumab
Biosimilar Relapsing–remitting
Bone Marrow Ocrelizumab
Brain Multiple sclerosis
Cladribine Genentech
Creatinine Natalizumab
Double Blind Cladribine
EU Immunology
Infusion Immunosuppressants
Intravenous Medical specialties
John Cunningham Monoclonal antibodies
Lymphoid Drugs
Multiple Sclerosis Lymphoid irradiation
Natalizumab MS
Organ Multiple sclerosis
PML Treatment groups
Relapse Parallel
Renal Impairment Transplantation
Rituximab
T Cell
T2 Weighted
Tysabri

Semantics

Type Source Name
disease MESH multiple sclerosis
gene UNIPROT AGL
disease MESH relapse
disease DOID relapsing-remitting multiple sclerosis
disease MESH relapsing-remitting multiple sclerosis
disease MESH multi
drug DRUGBANK Natalizumab
gene UNIPROT ALG3
gene UNIPROT NR4A2
drug DRUGBANK Creatinine
disease MESH renal
disease MESH diagnosis
gene UNIPROT PML
disease DOID PML
gene UNIPROT EHD1
drug DRUGBANK Cladribine
drug DRUGBANK Rituximab
drug DRUGBANK Daclizumab
drug DRUGBANK Ocrelizumab
drug DRUGBANK Alemtuzumab
disease DOID multiple sclerosis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *